Machine Learning in Drug Development: Part One, Volume 64 in the Annual Reports on Medicinal Chemistry series, highlights new advances in the field. Chapters in this release include Artificial Intelligence in Small Molecule and Nucleic Acid Research: A Review, AI-aided Drug Development for Protein Degraders: Design, Lead Identification, and Optimization, AI-aided Drug Development for Protein Degraders: Biology Validation, Disease-association, Drug Repurposing, Transforming Modern Drug Discovery with Machine Learning, Artificial Intelligence in the Development of Antiviral Drugs: Progress and Applications, Artificial Intelligence for Drug Target Identification, and Machine Learning in Proteomic Biomarker Discovery.
1. Title of Book - p. i 2. Cover image - p. i 3. Title page - p. ii 4. Table of Contents - p. iii 5. Series Page - p. iii 6. Copyright - p. iii 7. Contributors - p. vii 8. Preface - p. ix 9. Chapter One: Transforming modern drug discovery with machine learning – applications in ligand-based drug design - p. 1 10. Chapter Two: Advancing biomarker-driven precision medicine in renal cell carcinoma through statistical, machine learning, and subgroup analysis - p. 65 11. Chapter Three: Artificial intelligence for drug target identification - p. 91
Machine Learning in Drug Development: Part One, Volume 64 in the Annual Reports on Medicinal Chemistry series, highlights new advances in the field. Chapters in this release include Artificial Intelligence in Small Molecule and Nucleic Acid Research: A Review, AI-aided Drug Development for Protein Degraders: Design, Lead Identification, and Optimization, AI-aided Drug Development for Protein Degraders: Biology Validation, Disease-association, Drug Repurposing, Transforming Modern Drug Discovery with Machine Learning, Artificial Intelligence in the Development of Antiviral Drugs: Progress and Applications, Artificial Intelligence for Drug Target Identification, and Machine Learning in Proteomic Biomarker Discovery.
1. Title of Book - p. i 2. Cover image - p. i 3. Title page - p. ii 4. Table of Contents - p. iii 5. Series Page - p. iii 6. Copyright - p. iii 7. Contributors - p. vii 8. Preface - p. ix 9. Chapter One: Transforming modern drug discovery with machine learning – applications in ligand-based drug design - p. 1 10. Chapter Two: Advancing biomarker-driven precision medicine in renal cell carcinoma through statistical, machine learning, and subgroup analysis - p. 65 11. Chapter Three: Artificial intelligence for drug target identification - p. 91
